Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey - Takeaways - MDSpire

Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey

  • By

  • Tyler A. Lanman

  • L. Nicolas Gonzalez Castro

  • Haley K. Perlow

  • Gilbert Youssef

  • Roy E. Strowd

  • Michael T. Milano

  • Marina Kushnirsky

  • Ankush Bhatia

  • Patrick Y. Wen

  • Julie J. Miller

  • Benjamin J. Rich

  • June 8, 2026

  • 0 min

Share

  • 1

    IDH-mutant gliomas are defined by a pathogenic IDH mutation and are often diagnosed in individuals aged 30-40 years.

  • 2

    Treatment typically involves surgery, radiotherapy, and chemotherapy, with a watch-and-wait approach considered in some cases.

  • 3

    The Phase 3 INDIGO trial showed improved progression-free survival with the IDH inhibitor vorasidenib, leading to its FDA approval in 2024.

  • 4

    A survey of 153 clinicians revealed practice variation in treatment recommendations for IDH-mutant gliomas across specialties and institutions.

  • 5

    The survey aimed to assess how factors like age and tumor grade influence treatment decisions among neuro-oncologists and radiation oncologists.

Original Source(s)

Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey

  • by Tyler A. Lanman, L. Nicolas Gonzalez Castro, Haley K. Perlow, Gilbert Youssef, Roy E. Strowd, Michael T. Milano, Marina Kushnirsky, Ankush Bhatia, Patrick Y. Wen, Julie J. Miller, Benjamin J. Rich

  • June 8, 2026

Related Content

Reporting of Rurality, Deprivation, and Socioeconomic Characteristics in Cancer Clinical Trials: A Systematic

Distribution analysis of gynecological carcinomas with concurrent second primary carcinomas

Case Report: First report of PIK3CA-related overgrowth spectrum revealed by refractory chylorrhea after breast-conserving surgery: failed thoracic-duct ligation